Abstract
The identification and validation of predictive biomarkers has often been hampered by issues in retrospective clinical study design, for example missing control groups and small or biased patient series. Despite a wealth of preclinical mechanistic insights and finished randomized controlled trials (RCT), translation to the clinic is infrequent. XIST and 53BP1 are two genes that were previously identified in preclinical studies to predict resistance to therapy targeting BRCA1 deficiency. We studied the expression of these two genes in the context of an RCT randomizing between conventional (5 cycles fluorouracil, epirubicin, cyclophosphamide (FEC)) and BRCA1 defect targeting chemotherapy (4 cycles FEC + 1 cycle of high dose carboplatin, thiotepa, cyclophosphamide).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
